SAN DIEGO, June 5, 2012 /PRNewswire/ -- Based on its comprehensive TEAM Research™ rigorous 10 step evaluation methodology, Frost & Sullivan has awarded Pfenex Inc. with the 2012 North American Enabling Technology Award in Microbial Expression Technology. Frost & Sullivan industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
In order to be selected for the prestigious Enabling Technology Award, the following criteria were used to benchmark Pfenex's performance against its key competitors:
- Enables Creation of New Products
- Enhances Current Products
- Enables New Applications
- Potential for Market Acceptance
- Delivery of Technology to Market
Overcoming historic bottleneck issues in biopharmaceutical development, Pfenex Inc. through its Pseudomonas fluorescens-based platform, Pfenex Expression Technology™, offers a novel microbial expression technology that has demonstrated its ability to rapidly and repeatedly produce difficult-to-express proteins.
"Their speed and success rate is unparalleled in this market," says Frost & Sullivan Industry Analyst Sangeetha Prabakar. "With rapid development, high yield and uncompromised quality, this platform has been used for the production of not only innovator biologics, but also biosimilars and reagent proteins. This technology platform has enabled several developers to take their products towards clinical development, which otherwise would have been abandoned due to production challenges."
"On behalf of the entire Pfenex team and investors we are honored to receive this prestigious award from Frost & Sullivan," said Dr. Bertrand C. Liang, Chief Executive Officer of Pfenex, "Pfenex has developed a platform that transcends legacy protein production technologies, and this award serves as validation of that effort."
About Pfenex Inc.
Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com
SOURCE Pfenex Inc.